A descriptive analysis of real-world oncology biosimilar use in Japan
Open Access
- 12 June 2024
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (25) , 1837-1850
Abstract
Aim: To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan.Keywords
Funding Information
- Pfizer Inc
This publication has 35 references indexed in Scilit:
- Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancerBreast Cancer Research and Treatment, 2023
- Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022BioDrugs, 2023
- Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database studyCancer Medicine, 2023
- Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018Breast Cancer, 2022
- Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind StudyBioDrugs, 2022
- Analysis of nationwide hemophilia care: A cohort study using two Japanese healthcare claims databasesHealth Science Reports, 2022
- Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database StudyAdvances in Therapy, 2021
- A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)BioDrugs, 2019
- PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind StudyBioDrugs, 2019
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2019